MX2021005240A - Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. - Google Patents

Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.

Info

Publication number
MX2021005240A
MX2021005240A MX2021005240A MX2021005240A MX2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A
Authority
MX
Mexico
Prior art keywords
combination
inhibitors
cancer agents
small molecule
blocking agent
Prior art date
Application number
MX2021005240A
Other languages
English (en)
Spanish (es)
Inventor
Pottayil Govindan Nair Sasikumar
Muralidhara Ramachandra
Girish Chandrappa Daginakatte
Kiran Aithal Balkudru
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of MX2021005240A publication Critical patent/MX2021005240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021005240A 2018-11-08 2019-11-08 Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. MX2021005240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Publications (1)

Publication Number Publication Date
MX2021005240A true MX2021005240A (es) 2021-06-18

Family

ID=69159806

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021005240A MX2021005240A (es) 2018-11-08 2019-11-08 Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
MX2024006094A MX2024006094A (es) 2018-11-08 2021-05-04 Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024006094A MX2024006094A (es) 2018-11-08 2021-05-04 Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.

Country Status (14)

Country Link
US (3) US11311517B2 (enExample)
EP (1) EP3876931A1 (enExample)
JP (2) JP7623279B2 (enExample)
KR (1) KR20210088584A (enExample)
CN (2) CN120305258A (enExample)
AU (1) AU2019375193A1 (enExample)
BR (1) BR112021008781A2 (enExample)
CA (1) CA3118843A1 (enExample)
EA (1) EA202190776A1 (enExample)
IL (1) IL282972B2 (enExample)
MX (2) MX2021005240A (enExample)
PH (1) PH12021550832A1 (enExample)
SG (1) SG11202104192TA (enExample)
WO (1) WO2020095256A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087841A1 (en) * 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
JP2024508395A (ja) * 2021-02-10 2024-02-27 グレート ノベル セラピューティクス バイオテック アンド メディカルズ コーポレイション がんに対する免疫応答を刺激する又は免疫抑制を克服するための医薬組み合わせ及び方法
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
AU2024363740A1 (en) 2023-10-19 2026-04-02 Aurigene Oncology Limited Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
WO2025229629A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited Combination therapy using a cd47-sirp-alpha blocking agent and azacitidine
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104501B1 (en) * 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
KR102894264B1 (ko) * 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EP3283175B1 (en) 2015-04-14 2026-05-06 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
WO2017053423A1 (en) 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
EP3454879B1 (en) 2016-05-10 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New compounds and pharmaceutical use thereof in the treatment of cancer
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
AU2017345500B2 (en) * 2016-10-20 2022-03-10 Aurigene Oncology Limited Dual inhibitors of vista and PD-1 pathways
CA3087841A1 (en) * 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
CN118236374A (zh) * 2018-03-14 2024-06-25 奥瑞基尼肿瘤有限公司 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法

Also Published As

Publication number Publication date
US12268670B2 (en) 2025-04-08
PH12021550832A1 (en) 2021-10-04
CN112930181B (zh) 2025-05-13
SG11202104192TA (en) 2021-05-28
JP2022507025A (ja) 2022-01-18
IL282972B2 (en) 2025-06-01
CA3118843A1 (en) 2020-05-14
US11311517B2 (en) 2022-04-26
IL282972B1 (en) 2025-02-01
CN120305258A (zh) 2025-07-15
JP2025063207A (ja) 2025-04-15
MX2024006094A (es) 2024-05-30
EA202190776A1 (ru) 2021-09-20
US20200147054A1 (en) 2020-05-14
EP3876931A1 (en) 2021-09-15
AU2019375193A1 (en) 2021-05-13
CN112930181A (zh) 2021-06-08
US20220241248A1 (en) 2022-08-04
BR112021008781A2 (pt) 2021-08-03
US20250177358A1 (en) 2025-06-05
WO2020095256A1 (en) 2020-05-14
IL282972A (en) 2021-06-30
JP7623279B2 (ja) 2025-01-28
KR20210088584A (ko) 2021-07-14

Similar Documents

Publication Publication Date Title
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CL2023000847A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CO2023001561A2 (es) Combinaciones para el tratamiento de cáncer
MX2024002016A (es) Inhibidor de sos1 y uso del mismo.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2020012137A (es) Inhibidores de mcl-1.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2022000270A2 (es) Inhibidores de enzimas
DOP2022000107A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CO2025012293A2 (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
MX2021002742A (es) Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
PH12021550815A1 (en) New combination solution for treating chemotherapy refractory cancer